#dcvax $nwbo #gbm

Thought this statement was interesting from the recent NICE recommendation:

'The company has a confidential commercial arrangement for each medicine through a simple discount patient access scheme which makes dabrafenib plus trametinib available to the NHS

💊Pembrolizumab in addition to Dabrafenib/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma
Thyroid Journal

✅Pembrolizumab added upfront or at progression vs dabra-trame alone
mOS: 17 vs 9 mo, p=0.03
mPFS: 11 vs 4 mo, p=0.04
✅If dabra-trame given as neoadjuvant,

Interested in #drug #treatment of #vascular and #lymphatic anomalies. #Sirolimus and #Trametinib are used in trials & off-label. Here combination of both, in lower dose, effective without increased toxicity #VASCAPA #HEVAS #ReVAMP #ISSVA #VASCERN #CMTC
rdcu.be/dIbvX

Impressive results for dabrafenib + trametinib in children with BRAF-V600 glioma, but haven't we reached consensus that waterfall plots should have the patients with progression on the left? ascopubs.org/doi/full/10.12…

Un gruppo di ricerca supportato da Fondazione AIRC ha scoperto che l’efficacia del trametinib potrebbe aumentare usandolo in combinazione con un altro farmaco, un immunoterapico. Scopri di più ➡️ bit.ly/3wzBy1S

NICE approve 1L Dabrafenib & Trametinib for BRAF V600E NSCLC

TEBRP GÜNCELLENDİ

TEBRP SUT Kontrol Uygulamalarına;
•BCG Canlı İntavezikal
•Kobimetinib
•Krizotinib
•Trametinib
•Vemurafenib
etkin maddelerinin SUT Kontrol Uygulamaları eklendi.
Web ve Mobil uygulamamızda, bu etkin maddeleri içeren müstahzarların SUT Özet sekmelerinden veya

Primero imatinib...en 2021 Everolimus, sunitinib, abiraretona, pazopanib, trametinib.Recientemente alectinib, olaparib, dasatinib,nilotinib,osimertinib.Cada vez serán más. Hay que ponerse manos a la obra S.E.F.H GEDEFO Grupo PK.gen SEFH AdhefarSefh
link.springer.com/article/10.100…

Wow!

Great talk by Kahana-Edwin
AV malformations have KRAS mutations and respond to the MEK inhibitor trametinib.
🎯Hitting the target
🎯Precision medicine beyond oncology

Just published!
The results of the Phase 2 study (BELIEVE study; NCCH1901) of dabrafenib-trametinib combination therapy across cancer types in Japan have just been published in eClinicalMedicine part of the Lancet discovery science. #presicionmedicine

sciencedirect.com/science/articl…

Hitting the targets— N-of-1🎯🎯
Can’t get over this beautiful complete remission by Demiray group. 🔥🔥Customized combination with trametinib (MEK) inhibitor and palbociclib (cdk4/6 inhibitor) for aggressive myxofibrosarxoma with RAF1 and cyclin alterations.

Targeted treatment in #complex #lymphatic
anomaly ( #CLA ): a case of #synergistic efficacy
of #trametinib and #sirolimus :
rdcu.be/dIbvX
Lowered dose, no increase in #adverse effects.
#VASCAPA #HEVAS #LYMPH #ISSVA #VASCERN #Orphanet #theralymph #Welbio #CMTC #lymphedema

Dabrafenib & trametinib in BRAF V600E/R BRAF mutated solid tumours
eClinicalMedicine – The Lancet Discovery Science
doi.org/10.1016/j.ecli…
🔎BELIEVE phs II, 50 pts, 7 tumor types incl CCC
👉ORR 28%, DCR 84%, PFS 6.5 mo, mOS 9.7 mo
🧐within expectations, additional line for pts w/ limited options
ESMO - Eur. Oncology

FDA approvals Tumor-Agnostic drugs:
dMMR
Pembrolizumab 2017
Dostarlimab 2022
MSI-H
Pembrolizumab 2017
TMB-High
Pembrolizumab 2020
NTRK fusions
Larotrectinib 2018
Entrectinib 2019
BRAF V600E
Dabrafenib + Trametinib 2022
RET fusions
Selpercatinib 2022
HER2 3+
T-derutxecan 2024

#tumoragnostic approvals can change the life of patients with oncogenic-driven cancers. 66 y/o male, never smoker with stage IV lung pleomorphic carcinoma was offered doxorubicin as a 1L tx. Plasma NGS detected #BRAF V600E mutation. Just 1 month of #dabrafenib + #trametinib !👇🏽

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in #KRAS or NRAS Mutant Advanced Solid Tumors.
bit.ly/4bsFMHk

Ten year ago Millie was diagnosed with a brain tumor. Now, 10 years later she is still in treatment on Trametinib and living her “Best Day Ever.” We appreciate all the support, encouragement and love she receives Happy Quail Jan Halash 🌻💙💛 Joe Baber National Brain Tumor Society

Here, Cournoyer and colleagues describe their experience with the #BRAF -inhibitor dabrafenib and the #MEK -inhibitor trametinib to treat patients with newly diagnosed or relapsed/refractory #Langerhans_cell_histiocytosis . haematologica.org/article/view/h…

📢 #ThyroidSpecialists : Attend our presentation 🗓️ Fri 5/5, 8am EST 🕗 on Dr. Leboulleux's study (Gustave Roussy) 🔬 on Redifferentiation Trial with Dabrafenib-Trametinib & 131-I in Metastatic Thyroid Cancer. ⚕️🦋 #MedTwitter #EndoTwitter